Tivic Health is a clinical-stage biopharmaceutical company developing Entolimod, a TLR5 agonist drug candidate designed to trigger bone marrow recovery, protect the GI mucosal lining, and mobilize immune cells. The company pivoted in early 2025, exiting its consumer health device business to focus entirely on Entolimod and its next-generation derivative, Entolasta. Tivic's primary near-term target is Acute Radiation Syndrome (ARS), the life-threatening condition resulting from high-dose whole-body radiation exposure. Entolimod is being developed as a medical countermeasure intended for procurement and stockpiling in the U.S. Strategic National Stockpile and by allied militaries, with the regulatory path running through the FDA's Animal Rule. Beyond ARS, Tivic is pursuing oncology indications where Entolimod could address radiation- and chemotherapy-induced neutropenia, thrombocytopenia, and radiation mucositis in head and neck cancer patients. Entolasta, a next-generation version engineered to reduce immunogenicity, is designed for indications requiring repeated dosing. To support Entolimod manufacturing, Tivic acquired biomanufacturing assets and formed Velocity Bioworks, a wholly owned CDMO subsidiary in San Antonio, TX, which also provides manufacturing services to third-party biopharma customers to partially offset operating costs. Tivic has no product revenue and is funded through equity raises and convertible preferred financing.